Lemtrada Panel Review Pivots On What Constitutes An Adequate, Well-Controlled Trial
This article was originally published in The Pink Sheet Daily
FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will be asked whether open-label, rater-blinded trials meet approval standards for Sanofi/Genzyme’s Lemtrada sBLA; agency reviewers say no.
You may also be interested in...
The paradigm shift long-lasting Lemtrada will excite, along with Aubagio’s gains since its launch in October, put Sanofi well on the road to its goal of multiple sclerosis leadership, Genzyme research execs say.
Proposal, which could be formally endorsed by MedPac this spring, would lower the payment rates for vaccines while simultaneously moving all preventative vaccine coverage to Medicare Part B. Commission signals further cuts to payment rate, through an average sales priced-based methodology that might eventually be recommended.
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.